Celldex Therapeutics vs Ibio
Celldex Therapeutics is the larger business, with $1.5m of revenue in fiscal 2025 against $100,000 for Ibio (15.4 times as much). Ibio grew faster (-75.0% against -78.0%). Celldex Therapeutics kept more of each dollar of sales as profit: a net margin of -16748.0% against -33044.0%. Celldex Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Celldex TherapeuticsCLDX, 2025 | IbioIBIO, 2026 |
|---|---|---|
| Revenue | $1.5m | $100,000 |
| Revenue growth | -78.0% | -75.0% |
| Net income | −$259m | −$33.0m |
| Operating margin | -18599.8% | -35141.0% |
| Net margin | -16748.0% | -33044.0% |
| Return on equity | -40.6% | -65.7% |
| Free cash flow | −$214m | −$23.8m |
| Cash | $28.9m | $56.4m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 198 | 23 |
| Market value | $2.32bn | $45.5m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 2 sales | 4 buys, 0 sales |